Nuwellis (NUWE) Projected to Post Earnings on Tuesday

Nuwellis (NASDAQ:NUWE) is expected to be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.00) per share and revenue of $2.0940 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last issued its quarterly earnings results on Tuesday, March 10th. The company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.56) by $0.06. The business had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.31 million. Nuwellis had a negative net margin of 211.86% and a negative return on equity of 6,094.26%.

Nuwellis Stock Down 1.9%

NUWE traded down $0.02 during trading on Tuesday, reaching $1.10. 16,201 shares of the stock traded hands, compared to its average volume of 1,558,815. The stock has a market capitalization of $2.70 million, a PE ratio of -0.01 and a beta of 0.25. The stock’s 50-day moving average is $1.24 and its 200 day moving average is $2.06. Nuwellis has a 12 month low of $0.96 and a 12 month high of $43.26.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.